Serper M, Weinberg EM, Cohen JB, et al. - Researchers analyzed a cohort suffering from cirrhosis and atrial fibrillation (AF) in this retrospective, longitudinal study to determine how all‐cause mortality and hepatic decompensation as well as ischemic stroke, major adverse cardiovascular events, splanchnic vein thrombosis, and bleeding in these patients could be impacted by anticoagulation (AC) with warfarin and direct oral anticoagulants (DOACs). This study involved 2,694 US veterans with cirrhosis with AF (n = 1,694 and n = 704 in the warfarin and DOAC cohorts following propensity score matching, respectively) with a median of 4.6 years of follow-up. Decreased all‐cause mortality was observed in relation to warfarin and DOACs vs no AC. More bleeding occurred with warfarin vs no AC. A lower incidence of bleeding was reported in relation to DOACs vs warfarin in exploratory analyses. Warfarin and DOACs were linked with reduced ischemic stroke, in marginal structural models.